GlassScriptPhysician profile
James St Pierre
NPI 1891751228
$14,623.73
in general payments reported to CMS, 2019-2025
42 companies · $1,707 in 2025
The $1,707 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,944 · 2020: $1,737 · 2021: $1,869 · 2022: $2,391 · 2023: $2,528 · 2024: $2,448 · 2025: $1,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,558 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,557.96 |
| Education | $124.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,647.20 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,231.05 | 2019-2025 | |
| Pfizer INC. | $1,108.37 | 2019-2025 | |
| Amgen INC. | $1,091.39 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $935.55 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $860.14 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $747.12 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $724.41 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $683.94 | 2021-2025 | Verquvo, Capvaxive |
| Alnylam Pharmaceuticals INC. | $628.82 | 2019-2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $586.74 | 2019-2024 | Farxiga, Wainua |
| Esperion Therapeutics, INC. | $557.66 | 2020-2024 | Nexletol |
| Boston Scientific Corporation | $399.67 | 2022-2024 | Watchman Access System, Watchman Flx, Watchman |
| Novo Nordisk INC | $386.09 | 2024-2025 | Ozempic, Wegovy |
| Impulse Dynamics (USA) INC. | $311.88 | 2022-2023 | Optimizer |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $281.07 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $277.57 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $238.32 | 2019-2022 | |
| Abbott Laboratories | $197.37 | 2019-2022 | |
| Scpharmaceuticals INC. | $190.21 | 2023-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $167.23 | 2023 | Arcalyst |
| Philips North America LLC | $165.87 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Actelion Pharmaceuticals US, INC. | $140.66 | 2023-2025 | Opsumit, Uptravi |
| Akcea Therapeutics, INC. | $128.96 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $101.58 | 2019-2025 | Evkeeza |
| Biotronik INC. | $95.08 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $89.36 | 2023-2024 | Inpefa |
| Lundbeck LLC | $84.11 | 2019-2020 | |
| Heartflow, INC. | $76.38 | 2022-2023 | Ffrct |
| Lilly USA, LLC | $73.96 | 2025 | Mounjaro, Zepbound |
| Bridgebio Pharma, INC. | $71.69 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $55.92 | 2025 | |
| Medtronic, INC. | $47.57 | 2023 | Hawkone |
| Bardy Diagnostics, INC. | $41.66 | 2019-2020 | |
| Cvrx, INC. | $32.60 | 2023 | Barostim Neo System |
| Astellas Pharma US INC | $31.81 | 2019 | |
| Medtronic Vascular, INC. | $29.38 | 2019 | |
| Sobi, INC | $27.23 | 2021 | |
| Agepha Pharma Fz LLC | $26.30 | 2024 | Lodoco |
| Amryt Pharma Holdings LTD | $19.96 | 2021 | |
| Allergan, INC. | $19.20 | 2019 | |
| Vifor Pharma, INC. | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James St Pierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.